Biosimilars: what do patients need to consider?


A view from the EULAR Standing Committee of People with Arthritis/Rheumatism in Europe (SCPARE) on some of the issues that patients might wish to consider about biosimilars in shared decision-making discussions with their rheumatologist. The paper also points to the need for more information on biosimilars being made available in lay language.

DOI: 10.1136/rmdopen-2015-000141

Extracted Key Phrases

Cite this paper

@inproceedings{Skingle2015BiosimilarsWD, title={Biosimilars: what do patients need to consider?}, author={Diana Skingle}, booktitle={RMD open}, year={2015} }